

Emir M MuzuroviÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8149383/publications.pdf>

Version: 2024-02-01

16
papers

295
citations

1039880

9
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

130
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Epicardial Adipocyte-derived TNF- α Modulates Local Inflammation in Patients with Advanced Coronary Artery Disease. <i>Current Vascular Pharmacology</i> , 2022, 20, 94-95. | 0.8 | 4 |
| 2 | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. <i>Hypertension</i> , 2022, 79, 1319-1326. | 1.3 | 50 |
| 3 | Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease—Pathogenesis and Pharmacological Treatment Options. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 25-39. | 1.0 | 13 |
| 4 | AST to ALT Ratio and Peripheral Arterial Disease in a Hypertensive Population—Is There a Link?. <i>Angiology</i> , 2021, 72, 905-907. | 0.8 | 2 |
| 5 | Approach to patients with European Network for the Study of Adrenal Tumor stages I and II adrenocortical carcinomas. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 265-270. | 1.2 | 3 |
| 6 | Homocysteine and diabetes: Role in macrovascular and microvascular complications. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107834. | 1.2 | 43 |
| 7 | Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110069. | 1.0 | 17 |
| 8 | Re: Iglay K, Hannachi H, Engel SS, et al. Comorbidities in type 2 diabetes patients with and without atherosclerotic cardiovascular disease: a retrospective database analysis. <i>Curr Med Res Opin</i> . 2021. DOI:10.1080/03007995.2021.1895736. <i>Current Medical Research and Opinion</i> , 2021, 37, 1293-1294. | 0.9 | 1 |
| 9 | Diagnosis and treatment of mediastinal ectopic thyroid tissue with normally located thyroid gland and primary hyperparathyroidism: a case report. <i>Gland Surgery</i> , 2021, 10, 1532-1541. | 0.5 | 3 |
| 10 | Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. <i>Metabolism: Clinical and Experimental</i> , 2021, 119, 154770. | 1.5 | 101 |
| 11 | Primary hyperparathyroidism associated with acquired long QT interval and ventricular tachycardia. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, . | 0.2 | 2 |
| 12 | Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. <i>Current Vascular Pharmacology</i> , 2021, 19, 582-584. | 0.8 | 4 |
| 13 | Inflammatory Markers Associated With Diabetes Mellitus — Old and New Players. <i>Current Pharmaceutical Design</i> , 2021, 27, 3020-3035. | 0.9 | 13 |
| 14 | Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2125-2135. | 0.9 | 18 |
| 15 | Weight-centric pharmacological management of type 2 diabetes mellitus — An essential component of cardiovascular disease prevention. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107619. | 1.2 | 11 |
| 16 | Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154305. | 1.5 | 10 |